Clinical Trials Logo

Filter by:
NCT ID: NCT05708664 Completed - Breast Cancer Clinical Trials

Precision Breast Conserving Surgery With Guidance.

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

From 2021 to 2022, 31 patients with unifocal breast cancer were enrolled for precision breast conserving surgery (PBCS) guided by wire guided localization (WGL) combined with CT guided 3D reconstruction. Surrounded WGL was performed under local anesthesia, followed by an immediate contrast enhanced CT scan. PBCS guided by CT guided 3D reconstruction was performed one day after the localization. Women who underwent palpation guided breast conserving surgery (BCS) were included as control. Two-sided Student t test, Fisher's exact test and chi-square test was applied.

NCT ID: NCT05708144 Completed - Breast Cancer Clinical Trials

NIR Fluorescent Molecular Probe for the Identification of Breast Tissue

NIR
Start date: February 17, 2023
Phase: N/A
Study type: Interventional

Accurate evaluation of tumor boundaries in breast-conserving surgery is critical to reducing the second operation of patients. Near-infrared (NIR) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly identify the tumor area of the resected breast tissue during the operation and distinguish the tumor boundary. In brief, the breast tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the tumor boundary. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.

NCT ID: NCT05707910 Recruiting - Malignant Tumor Clinical Trials

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety of therapeutic immunological agent against EBV-positive advanced malignancies, examining the incidence, type of occurrence, and severity of adverse events in relation to the agent tested, and initially exploring the effectiveness of the immunological agent.

NCT ID: NCT05707832 Not yet recruiting - Clinical trials for Invasive Aspergillosis

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

Start date: March 30, 2023
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label, non-controlled, single-arm clinical trial to evaluate the safety, efficacy and population pharmacokinetics of Amphotericin B cholesteryl Sulfate Complex for Injection domestic formulations (ABCD) in the treatment of confirmed invasive candidiasis (IC) and confirmed/clinically diagnosed invasive aspergillus (IA) disease.

NCT ID: NCT05707819 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Start date: July 30, 2022
Phase:
Study type: Observational

The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.

NCT ID: NCT05707767 Recruiting - Surgery Clinical Trials

A Prospective Study of Surgical Treatment Strategies for Chordoma

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

NCT ID: NCT05707676 Recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)

MEETCD8-001
Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors

NCT ID: NCT05707598 Completed - Colorectal Cancer Clinical Trials

Multivisceral Radical Resection for Surgical T4b Colorectal Cancer: Propensity Score-matched Study Comparing the the Laparoscopic and Open Approaches

C-PelvEx-01
Start date: January 1, 2023
Phase:
Study type: Observational

This study attempts to compare safety and long-term oncological outcomes between laparoscopic surgery and open surgery in the treatment of clinical T4b Colorectal cancer.

NCT ID: NCT05707585 Recruiting - Lung Cancer Clinical Trials

Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

Start date: January 29, 2023
Phase:
Study type: Observational

The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage. This study will mainly focus on varifing the previously identified epigenetic imprinting biomarkers for lung cancer and upgrading and validating a lung cancer imprinting diagnostic model specifically for bronchoalveolar lavage. The lavage sample will be collected from each eligible paticipants under bronchialscopy and undergo QCIGISH detection to analyze the allelic expression status of imprinted genes. The QCIGISH detection results will be compared with the final surgical histopathology. No interventions will be taken according to the QCIGISH detection results.

NCT ID: NCT05707533 Completed - Clinical trials for Pelvic Organ Prolapse

Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse

Start date: August 1, 2022
Phase:
Study type: Observational

After obtaining an institutional ethics approval (#2021833), the investigators retrospectively reviewed patients with Pelvic organ prolapse (POP) who underwent Transvaginal Mesh (TVM) in their hospital during June 2008 and December 2020. The goal of this observational study is to introduce the Vaginal Adventitia Reserved and Anatomical Implant Technique in Transvaginal mesh surgery, and to report long term efficacy and safety results of this technique. The main questions it aims to answer are: - How to reduce the potential risk of mesh-related complications when performing TVM? - How effective is the use of the Vaginal Adventitia Reserved and Anatomical Implant Technique when performing TVM? Participants will be asked to fill the Pelvic Floor Distress Inventory (PFDI-20) at final follow-up, and the Prosthesis/Graft Complication Classification Code was used to record the mesh-related complications.